Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines

The introduction and rollout of a meningococcal serogroup A conjugate vaccine, MenAfriVac, in the African meningitis belt has eliminated serogroup A meningococcal infections for >300 million Africans. However, serogroup C, W, and X meningococci continue to circulate and have been responsible for...

Descripción completa

Detalles Bibliográficos
Autores principales: Alderson, Mark R, LaForce, F Marc, Sobanjo-ter Meulen, Ajoke, Hwang, Angela, Preziosi, Marie-Pierre, Klugman, Keith P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822963/
https://www.ncbi.nlm.nih.gov/pubmed/31671447
http://dx.doi.org/10.1093/infdis/jiz297
Descripción
Sumario:The introduction and rollout of a meningococcal serogroup A conjugate vaccine, MenAfriVac, in the African meningitis belt has eliminated serogroup A meningococcal infections for >300 million Africans. However, serogroup C, W, and X meningococci continue to circulate and have been responsible for focal epidemics in meningitis belt countries. Affordable multivalent meningococcal conjugate vaccines are being developed to prevent these non-A epidemics. This article describes the current epidemiologic situation and status of vaccine development and highlights questions to be addressed to most efficiently use these new vaccines.

Ejemplares similares